Adjuvant Chemotherapy After Gross‑Total Resection and Craniospinal Irradiation for Medulloblastoma

Risk Stratification and Radiation Parameters

• Average‑risk patients are defined as having no metastatic disease (M0), classic histology, and gross‑total or near‑total resection with residual tumor < 1.5 cm²; they receive 23.4 Gy craniospinal irradiation (CSI) with a posterior‑fossa boost to 55.8 Gy, and start adjuvant chemotherapy 6 weeks after radiation completion. 1
• High‑risk patients include those with metastatic disease (M+), subtotal resection leaving residual > 1.5 cm², or large‑cell/anaplastic histology; they receive 36 Gy CSI with a primary‑site boost to 54–55.8 Gy, followed by chemotherapy beginning 6 weeks post‑radiation. 1
• Very high‑risk patients are identified by MYC amplification; they receive 36 Gy CSI with boost to 54–55.8 Gy, and for Group 3 tumors carboplatin is administered as a radiosensitizer before each radiation fraction, with intensified adjuvant chemotherapy thereafter. 1

Chemotherapy Protocols

• Children’s Oncology Group (COG) regimen comprises vincristine, lomustine (CCNU), and cisplatin delivered in cycles over approximately 12 months; routine monitoring for vincristine‑associated neuropathy is required throughout treatment. (Phase III evidence) [2][1]
• St. Jude regimen is an alternative validated maintenance protocol with a distinct drug combination; it must be used as a complete regimen and cannot be switched to or from the COG protocol during therapy. (Guideline recommendation) 1

Critical Timing

• Initiation of adjuvant chemotherapy must occur 6 weeks after completing radiation to allow bone‑marrow recovery while avoiding delay of systemic therapy that could permit micrometastatic progression. (Guideline recommendation; supported by phase III rationale) [1][2]

Molecular‑Specific Considerations

• In Group 3 medulloblastoma with high‑risk features, concurrent carboplatin given before each radiation fraction improves event‑free survival by ≈ 19 % (randomized phase III trial). (Level I evidence) 1
• Stem‑cell collection should be considered before radiation in high‑risk patients to preserve the option of autologous stem‑cell rescue if disease recurs. (Phase III evidence) 2

Evidence Hierarchy

• The 2025 NCCN Pediatric CNS Cancer Guidelines constitute the most authoritative source, superseding the 2013 NCCN version and integrating molecular subtyping (WNT, SHH, Group 3, Group 4) into risk assessment. (Guideline, high‑level) 1
• A phase III trial of > 400 patients aged 3–21 years demonstrated an 86 % 5‑year overall survival with post‑irradiation cisplatin‑based chemotherapy. (Phase III) 2

Adult Patient Considerations

• Evidence for adjuvant chemotherapy in adults is less robust; however, 36 Gy CSI with a boost to 55.8 Gy followed by cisplatin‑based chemotherapy is increasingly employed for high‑risk adult medulloblastoma. (Guideline, moderate evidence) 2

Common Pitfalls (Guideline Alerts)

• Do not delay chemotherapy beyond 6 weeks after radiation without a compelling medical reason, as this may compromise disease control. 1
• Do not interchange COG and St. Jude protocols mid‑treatment; each is designed as a complete, non‑interchangeable regimen. 1
• Do not omit carboplatin radiosensitization for high‑risk Group 3 tumors during radiation, given its proven survival benefit. 1
• Monitor vincristine‑induced neuropathy closely throughout maintenance therapy, as it is a major dose‑limiting toxicity. 1

Craniospinal Radiation Guidelines for Medulloblastoma

Introduction to Radiation Therapy

• The standard protocol for pediatric patients with medulloblastoma requiring craniospinal irradiation consists of 23.4 Gy to the craniospinal axis for average-risk patients or 36 Gy for high-risk patients, followed by a posterior fossa boost to 55.8 Gy, combined with adjuvant chemotherapy, as recommended by the National Comprehensive Cancer Network 3, 4, 5

Risk Stratification

• Average-risk criteria include M0 disease, classic histology, and gross total resection or near-total resection with residual tumor <1.5 cm², as defined by the National Comprehensive Cancer Network 3, 5
• High-risk criteria include M+ disease, subtotal resection or residual tumor >1.5 cm², and large cell or anaplastic histology, as defined by the National Comprehensive Cancer Network 3, 4, 5

Radiation Dose Schema

• For average-risk patients, the recommended craniospinal irradiation dose is 23.4 Gy, followed by a posterior fossa boost to 55.8 Gy, as recommended by the National Comprehensive Cancer Network 3, 4, 5
• For high-risk patients, the recommended craniospinal irradiation dose is 36 Gy, followed by a primary site boost to 54-55.8 Gy, as recommended by the National Comprehensive Cancer Network 3, 4, 5

Technical Radiation Planning Details

• Contrast-enhanced brain MRI should be performed within 24-72 hours after surgery to define the tumor bed, as recommended by the National Comprehensive Cancer Network 3, 4, 5
• Spinal MRI should be delayed 2-3 weeks post-surgery to avoid false-positive findings from blood products, as recommended by the National Comprehensive Cancer Network 3, 4, 5

Integration with Chemotherapy

• Chemotherapy should be started 6 weeks after completing radiation, as recommended by the National Comprehensive Cancer Network 3
• The COG protocol and St. Jude protocol are two recommended chemotherapy regimens, as defined by the National Comprehensive Cancer Network 5

Proton Beam Therapy Considerations

• Proton beam therapy is strongly recommended for medulloblastoma when available, with Level B evidence from the Japanese Society for Radiation Oncology and the Japanese Society of Pediatric Hematology/Oncology 6, 7, 8, 9, 10

Critical Pitfalls to Avoid

• Reducing craniospinal dose below 23.4 Gy for average-risk patients without intensive chemotherapy may increase relapse risk, as shown in a randomized trial 3, 4
• Performing spinal MRI immediately post-surgery may lead to false-positive findings from surgical blood products, as recommended by the National Comprehensive Cancer Network 3, 4, 5

Optimal Timing, Dose, and Pre‑Radiation Workup for Craniospinal Irradiation in Medulloblastoma

Timing Recommendations

• Initiate craniospinal irradiation (CSI) within 28–30 days after gross‑total resection in pediatric patients, with an absolute maximum allowable interval of 42 days, to optimize survival outcomes (National Comprehensive Cancer Network [NCCN] guideline) 11.
• The NCCN 2025 pediatric CNS cancer guideline specifies that most clinical trials require CSI to start no later than 30 days post‑resection, because delays beyond this window have been shown to worsen disease control 11.
• Upcoming EORTC and Alliance adult medulloblastoma trials set the upper limit for the interval from surgery to CSI at 42 days, establishing this as the maximum acceptable delay for adults (EORTC/Alliance trial design) 11.

Risk‑Stratified CSI Dose and Schedule

Average‑Risk Patients

• Prescribe 23.4 Gy CSI with a posterior‑fossa boost to a total dose of 54 Gy, commencing within the 28–30‑day postoperative window (NCCN 2025 recommendations) [12][13].
• Average‑risk classification includes M0 disease, classic histology, and gross‑total or near‑total resection with residual tumor < 1.5 cm² (NCCN 2025 criteria) [12][13].

High‑Risk Patients

• Prescribe 36 Gy CSI with a primary‑site boost to 54–55.8 Gy, also initiated within 28–30 days after surgery (NCCN 2025 recommendations) [12][13].
• High‑risk classification comprises M+ disease, subtotal resection with residual > 1.5 cm², or large‑cell/anaplastic histology (NCCN 2025 criteria) [12][13].

Very High‑Risk (MYC‑Amplified / Group 3) Patients

• Deliver 36 Gy CSI with a boost to 54–55.8 Gy, adding concurrent carboplatin administered before each radiation fraction for Group 3 tumors (NCCN 2025 protocol) [12][13].

Pre‑Radiation Imaging and Staging

• Delay spinal MRI for 2–3 weeks after surgery to avoid false‑positive enhancement from postoperative blood products (Neuro‑Oncology recommendation) 14.
• Complete disease staging with a full craniospinal MRI and cerebrospinal‑fluid cytology before radiation planning (Neuro‑Oncology recommendation) 14.

Molecular Testing Requirements

• Obtain adequate tumor tissue at the time of initial surgery for molecular classification (WNT, SHH, Group 3, Group 4), as these results are essential for risk stratification and treatment planning (NCCN 2025 guidance) [12][13].
• Do not omit molecular testing; for Group 3 tumors with high‑risk features, concurrent carboplatin radiosensitization improves event‑free survival by approximately 19 % (NCCN 2025 evidence) [12][13].

Adult‑Specific Considerations

• The NOA‑07 pilot trial for adult medulloblastoma reported a median interval of 53 days from resection to radiochemotherapy, indicating modest flexibility in adult scheduling (NOA‑07 trial data) 11.
• Nevertheless, the NCCN emphasizes that avoiding unnecessary delays remains critical in adults, as prolonged intervals are likely to compromise outcomes across all age groups (NCCN 2020 statement) 11.